Abstract 183P
Background
Personalized targeted cancer treatment strongly depends on genetic tests in tumor tissue. Meanwhile, it is essential to understand the oncogenicity of a large number of somatic and germline variants to identify potential drug targets, which can be used for further treatment. An adopted classification scheme to guide variant oncogenicity assessment has to be easy, fast and reproducible. In this study we implemented a full-fledged database SomaVar and web-based frontend for somatic variant upload, annotation and classification using the VICC classification guidelines.
Methods
The frontend provides a multitude of utility functions which include an advanced variant search, user defined variant lists, automatic classification criteria selection and extensive administrative utilities. SomaVar supports variant annotation including in-silico pathogenicity prediction scores, splicing prediction scores, third party classifications, population scores and protein domains. SomaVar has a semi-automatic classification algorithm for oncogenicity based on the VICC standards and allows harmonized consensus classification between different users.
Results
Using a list of variants already classified by experts we show that the automatic classification algorithm provides a high-quality preselection for most VICC criteria. This not only increases the speed at which experts can classify variants, but also increases quality by mitigating human error. We also compared our knowledgebase to OnkoKB. A large overlap was found within the both groups of variants of likely oncogenic and of unclear oncogenicity variants. Interestingly, divergent classification was observed for variants located within splice regions and for benign variants listed in gnomAD at high allele frequencies.
Conclusions
To date, our knowledgebase harbors over 20.000 classified somatic variants and continues to grow. This open-source knowledgebase is publicly available online.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
162P - Tailoring patient molecular selection for novel anti-MET therapies
Presenter: Lucia Notario Rincon
Session: Cocktail & Poster Display session
Resources:
Abstract
163TiP - Single-institution, single-arm, open-label phase II basket study of mutation and/or elevated hedgehog (Hh) expression-directed smoothened inhibitor sonidegib in patients with advanced solid malignancies
Presenter: Madhawa De Silva
Session: Cocktail & Poster Display session
Resources:
Abstract
164TiP - MONSTAR-GLYCO: A multi-institutional prospective study harnessing glycomics and multi-omics on the j-glyconet and SCRUM-MONSTR platform
Presenter: Tadayoshi Hashimoto
Session: Cocktail & Poster Display session
Resources:
Abstract
166P - Unravelling HR-positive, HER2-negative breast cancer and its tumor microenvironment heterogeneity using spatial transcriptomics
Presenter: Bengisu Karakose
Session: Cocktail & Poster Display session
Resources:
Abstract
167P - Cancer neutrophil encyclopedia: A deep dive into antigen-presenting warriors
Presenter: Yingcheng Wu
Session: Cocktail & Poster Display session
Resources:
Abstract
168P - Tumor microenvironment (TME) and PD-L1 expression heterogeneity in high grade serous ovarian cancer (HGSC) samples analysis from the randomized NeoPembrOV/GINECO phase II trial
Presenter: Laetitia Collet
Session: Cocktail & Poster Display session
Resources:
Abstract
169P - Tumour microenvironment in glioblastoma: A single-cell perspective on macrophage dynamics and T cell exhaustion
Presenter: Farasat Kazmi
Session: Cocktail & Poster Display session
Resources:
Abstract
170P - Digital spatial profiling to uncover biomarkers for response prediction in locally advanced gastric cancer patients treated with neoadjuvant chemotherapy
Presenter: Chiara Molinari
Session: Cocktail & Poster Display session
Resources:
Abstract
171P - Immune-modulatory drug profiling using perfused, microfluidic on-chip co-cultures of patient-derived ovarian cancer microtumors and autologous immune cells
Presenter: Sarah Plöger
Session: Cocktail & Poster Display session
Resources:
Abstract
172P - The impact of androgen ablation on the immune landscape in therapy-resistant prostate cancer: Insights from tumour microenvironment analysis
Presenter: Jodi Stewart
Session: Cocktail & Poster Display session
Resources:
Abstract